Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey

Clemente Ponzetti,1 Monica Canciani,2 Massimo Farina,2 Sara Era,3 Stefan Walzer4,5 1Group Policlinic Monza, Alessandria, National Scientific Associazione Nazionale dei Medici delle Direzioni Ospedaliere (National Association of Hospital Physicians), Bologna, 2Studio EmmEffe S.r.l, Milan, 3Roche S.p....

Full description

Bibliographic Details
Main Authors: Ponzetti C, Canciani M, Farina M, Era S, Walzer S
Format: Article
Language:English
Published: Dove Medical Press 2016-05-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
Health economics
cost savings
oncology
intravenous therapy
subcutaneous therapy
Online Access:https://www.dovepress.com/potential-resource-and-cost-saving-analysis-of-subcutaneous-versus-int-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/potential-resource-and-cost-saving-analysis-of-subcutaneous-versus-int-peer-reviewed-article-CEOR

Similar Items